登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>ROR1 >RO1-H821y

Biotinylated Human / Cynomolgus / Rhesus macaque ROR1 Protein, Avitag™ (MALS verified)

分子别名(Synonym)

ROR1,NTRKR1

表达区间及表达系统(Source)

Biotinylated Human / Cynomolgus / Rhesus macaque ROR1, Avitag (RO1-H821y) is expressed from human 293 cells (HEK293). It contains AA Gln 30 - Glu 403 (Accession # Q01973-1). In the region Gln 30 - Glu 403, the AA sequence of Human, Cynomolgus and Rhesus macaque ROR1 are homologus.

Predicted N-terminus: Gln 30

Request for sequence

蛋白结构(Molecular Characterization)

ROR1 Structure

This protein carries an Avi tag (Avitag™) at the C-terminus.

The protein has a calculated MW of 45.2 kDa. The protein migrates as 55-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

标记(Labeling)

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

蛋白标记度(Protein Ratio)

Passed as determined by the HABA assay / binding ELISA.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>95% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

ROR1 SDS-PAGE

Biotinylated Human / Cynomolgus / Rhesus macaque ROR1, Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-MALS

ROR1 SEC-MALS

The purity of Biotinylated Human / Cynomolgus / Rhesus macaque ROR1, Avitag (Cat. No. RO1-H821y) is more than 90% and the molecular weight of this protein is around 50-70 kDa verified by SEC-MALS.

Report

 

活性(Bioactivity)-ELISA

ROR1 ELISA

Immobilized Anti-ROR1 Antibody, Human IgG1 at 1 μg/mL (100 μL/well) can bind Biotinylated Human / Cynomolgus / Rhesus macaque ROR1, Avitag (Cat. No. RO1-H821y) with a linear range of 0.4-13 ng/mL (QC tested).

Protocol

 

活性(Bioactivity)-FACS

ROR1 FACS

2e5 of anti-ROR1 CAR-293 cells were stained with 100 μL of 3 μg/mL of Biotinylated Human / Cynomolgus / Rhesus macaque ROR1, Avitag (Cat. No. RO1-H821y) and negative control protein respectively, washed and then followed by PE-SA and analyzed with FACS (Routinely tested).

Protocol

 

背景(Background)

Tyrosine-protein kinase transmembrane receptor ROR1 is also known as Neurotrophic tyrosine kinase, receptor-related 1 (NTRKR1), which belongs to the protein kinase superfamily or tyr protein kinase family or ROR subfamily. ROR1 contains 1 FZ (frizzled) domain, 1 Ig-like C2-type (immunoglobulin-like) domain, 1 kringle domain, 1 protein kinase domain. ROR1 is expressed at high levels during early embryonic development. The expression levels drop strongly around day 16 and there are only very low levels in adult tissues. Isoform Short is strongly expressed in fetal and adult CNS and in a variety of human cancers, including those originating from CNS or PNS neuroectoderm. ROR1 could interact with casein kinase 1 epsilon (CK1ε) to activate phosphoinositide 3-kinase-mediated AKT phosphorylation and cAMP-response-element-binding protein (CREB), which was associated with enhanced tumor-cell growth.

 

前沿进展

 
 
货号/价格
产品推荐
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
ROR1靶点信息
英文全称:Inactive tyrosine-protein kinase transmembrane receptor ROR1
中文全称:受体酪氨酸激酶样孤儿受体1
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:12详情
最高研发阶段:临床三期
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定